Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences
05:34pm, Monday, 29'th Mar 2021
PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced t
3 High-Quality Picks for the Value Investor
10:45am, Thursday, 11'th Mar 2021
Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
10:37am, Tuesday, 02'nd Mar 2021
Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome.
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2020 Results - Earnings Call Transcript
01:58pm, Monday, 01'st Mar 2021
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2020 Results - Earnings Call Transcript
Recap: Reata Pharmaceuticals Q4 Earnings
07:06am, Monday, 01'st Mar 2021
Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 21.38% over the past year to ($1.25), which beat the
ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY'S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME
Reata Pharmaceuticals, Inc. Submits NDA for Company's Lead Program: Bardoxolone in Alport Syndrome
06:30am, Monday, 01'st Mar 2021
PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced t
PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced th
These 3 Stocks Will Double -- If Wall Street Has Its Way
05:05am, Wednesday, 03'rd Feb 2021
Analysts are excited about these companies. Should you be, too?
New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between
NEW YORK, Dec. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 a
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between Octobe
Los Angeles, California--(Newsfile Corp. - December 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmac
New York, New York--(Newsfile Corp. - December 10, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwe
